TCIM
OREX

TIAA CREF Investment Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

TIAA CREF Investment Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-42,553
Closed -$239K – 3288
2016
Q1 		$239K Sell
42,553
-24,869
-37% -$323K ﹤0.01% 2957
2015
Q4 		$1.16M Hold
67,422
– – ﹤0.01% 2492
2015
Q3 		$1.42M Sell
67,422
-12,897
-16% -$442K ﹤0.01% 2356
2015
Q2 		$3.98M Sell
80,319
-5,391
-6% -$322K ﹤0.01% 1851
2015
Q1 		$6.71M Sell
85,710
-39,573
-32% -$2.45M ﹤0.01% 1422
2014
Q4 		$7.59M Buy
125,283
+52,211
+71% +$2.62M 0.01% 1329
2014
Q3 		$3.11M Sell
73,072
-665
-0.9% -$35.7K ﹤0.01% 1929
2014
Q2 		$4.56M Buy
73,737
+15,692
+27% +$912K ﹤0.01% 1753
2014
Q1 		$3.77M Buy
58,045
+10,776
+23% +$729K ﹤0.01% 1823
2013
Q4 		$2.66M Buy
47,269
+1,219
+3% +$68.5K ﹤0.01% 2077
2013
Q3 		$2.83M Sell
46,050
-824
-2% -$55.8K ﹤0.01% 1991
2013
Q2 		$2.74M Buy
+46,874
New +$2.88M ﹤0.01% 1963

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TIAA CREF Investment Management's OREX Position: Q2 2016 in Review

TIAA CREF Investment Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 42,553 shares — an estimated $239K sold.

TIAA CREF Investment Management first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $7.59M in Q4 2014. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • TIAA CREF Investment Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • TIAA CREF Investment Management sold 42,553 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $239K.
  • TIAA CREF Investment Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • TIAA CREF Investment Management's Orexigen Therapeutics, Inc. position peaked at $7.59M in Q4 2014.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on TIAA CREF Investment Management's 13F filing for Q2 2016, filed 11 Aug 2016.